Results 141 to 150 of about 1,665 (152)

Intein-mediated rapid purification and characterization of a novel recombinant agonist for VPAC2

Peptides, 2006
In order to obtain the recombinant VPAC2 agonist efficiently by intein-mediated single column purification, a gene encoding 32-amino acids peptide was designed, synthesized and cloned into Escherichia coli expression vector pKYB. The recombinant vector pKY-ROM was transferred into E.
Rong-jie, Yu, Qiu-ling, Xie, Yun, Dai, Yuan, Gao, Tian-hong, Zhou, An, Hong   +5 more
openaire   +2 more sources

In Silico Classification and Prediction of VIP Derivatives as VPAC1/ VPAC2 Receptor Agonists/Antagonists

Combinatorial Chemistry & High Throughput Screening, 2015
Vasoactive intestinal polypeptide (VIP) is an intrinsic 28-amino acid peptide, involved in a wide range of physiologic effects, and therefore considered as a promising drug candidate for the treatment of several diseases. But the clinical application of VIP has been limited for the easy in vivo digestion.
Jiazhong, Li, Xin, Wang, Huanxiang, Liu, Hongyu, Li   +3 more
openaire   +2 more sources

[Expression and characterization of VPAC2 in CHO cells].

Sheng wu gong cheng xue bao = Chinese journal of biotechnology, 2010
VPAC2 is a co-receptor of pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) and mediates multiple bio-functions. In order to construct the CHO line expressing VPAC2 stably, pcDNA-VPAC2 was used to transfect CHO cells. The positive clones were selected by G418 and the clone VPAC2-CHO with high sensitivity
Rong-Jie, Yu, Yuan, Gao, Yun, Dai, Ngai-lik, Tam, Zhi-Hong, Zeng, Tian-Hong, Zhou, An, Hong   +6 more
openaire   +1 more source

Development of Selective Ligands for Pac1, Vpac1 and Vpac2 Receptors

2003
At the time of its isolation, purification and sequencing in 1970-1972 by Said and Mutt (Said and Mutt, 1972;Mutt and Said, 1974), VIP was the third identified member of a peptide group that included secretin (Mutt et al, 1970) and glucagon (Bromer et al, 1957).
P. Robberecht, P. Vertongen, I. Langer, J. Perret   +3 more
openaire   +1 more source

VPAC2 Receptors Mediate Vasoactive Intestinal Peptide-Induced Neuroprotection against Neonatal Excitotoxic Brain Lesions in Mice

The Journal of Pharmacology and Experimental Therapeutics, 2005
Prepro-vasoactive intestinal peptide (VIP) mRNA codes for two neuropeptides: VIP and peptide histidine isoleucine (PHI). Two VIP receptors, shared with a similar affinity by pituitary adenylate cyclase-activating polypeptide (PACAP), have been cloned: VPAC(1) and VPAC(2). PHI binds to these receptors with a lower affinity.
Rangon, Claire-Marie, Goursaud, Stéphanie, Medja, Fadia, Lelièvre, Vincent, Mounien, Lourdes, Husson, Isabelle, Brabet, Philippe, Jégou, Sylvie, Janet, Thierry, Gressens, Pierre   +9 more
openaire   +3 more sources

Activation of the VIP/VPAC2 system induces reactive astrocytosis associated with increased expression of glutamate transporters

Brain Research, 2011
Vasoactive intestinal peptide (VIP) is a pleiotropic neuropeptide that acts as a neuromodulator in the CNS. Recently, secretion of several functional molecules has been identified in VIP-stimulated astrocytes in vitro. However, the relationship between VIP and its specific receptors in neurological disorders remains unknown.
Mika, Nishimoto, Hiroyoshi, Miyakawa, Keiji, Wada, Akiko, Furuta   +3 more
openaire   +2 more sources

Circadian phenotype of double mutant PAC1/VPAC2 receptor knockout mice

Regulatory Peptides, 2012
J. Hannibal, J. Fahrenkrug
openaire   +1 more source

DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH VASOACTIVE INTESTINAL PEPTIDE RECEPTOR 2 (VPAC2)

2003
The invention provides a human VPAC2 which is associated with the disorders of the peripheral and central nervous system, cardio-vascular diseases, hematological diseases, genitourinary diseases, inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and ...
BAYER AG, GOLZ STEFAN, BRUEGGEMEIER ULF, SUMMER HOLGER   +3 more
openaire   +1 more source

VPAC2 receptor, RO 251553, shows promise in asthma

Inpharma Weekly, 2003
openaire   +1 more source

Immunobiology of the VPAC2 Rezeptor

2010
openaire   +1 more source